Adnexus Therapeutics, Inc.: Considering the Exit
Posted: 21 May 2009
Date Written: November 11, 2008
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc., (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month collaboration or continue with Adnexus' planned IPO.
Suggested Citation: Suggested Citation